A3P Biomedical’s Stockholm3 test showed 90% sensitivity in detecting aggressive prostate cancer in a study of 12,670 men, outperforming traditional PSA screening.
Freenome’s updated SimpleScreen CRC blood test met all primary and secondary endpoints in clinical validation, with improved sensitivity for precancerous lesions and colorectal cancer.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
NeoGenomics has launched the first FDA-approved PTEN IHC companion diagnostic for prostate adenocarcinoma, enabling identification of patients with PTEN deficiency who may benefit from AstraZeneca’s capivasertib therapy.
The new service supports transplantation medicine for 13 million people across Northern California and Northern Nevada.
The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
The company is introducing blood-based assays for tau biomarkers and a platform to automate laboratory workflows.
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.